会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明公开
    • Blood-treating material
    • Mittel zur Blutbehandlung。
    • EP0107119A1
    • 1984-05-02
    • EP83109905.6
    • 1983-10-04
    • TORAY INDUSTRIES, INC.
    • Kodama, MasashiKatayama, YutakaTani, ToruTeramoto, KazuoMurakami, Matsuo
    • A61K47/00A61K37/20A61M1/36
    • A61K35/74A61K31/715G01N2400/50
    • The present invention provides (1) a blood-treating material comprising a lipopolysaccharide derived from cell walls of Gram-negative bacteria and immobilized by an insoluble carrier containing an amino group or a carboxyl group and (2) a process for producing the blood-treating material characterized by reacting a condensing agent with a mixture of the lipopolysaccharide and the insoluble carrier.
      Lipopolysaccharides have been known to have antitumor effects against malignant tumors. However, they could not be used safely, since their fatal doses are very close to the minimum effective doses in the treatment of the tumors.
      The present invention makes it possible to reduce the lethal toxicity of the above-mentioned lipopolysaccharides and provide a new blood-treating material that can be used safely for therapy of cancer, because this blood-treating material has antitumor effects similar to those of the lipopolysaccharides derived from cell walls of Gram-negative bacteria but no fatal effects.
    • 本发明提供(1)一种血液处理材料,其特征在于,含有衍生自革兰氏阴性细菌的细胞壁的脂多糖并通过含有氨基或羧基的不溶性载体固定的血液处理材料和(2) 其特征在于使缩合剂与脂多糖和不溶性载体的混合物反应。 已知脂多糖对恶性肿瘤具有抗肿瘤作用。 然而,它们不能安全使用,因为它们的致命剂量非常接近治疗肿瘤的最小有效剂量。 本发明使得可以降低上述脂多糖的致死毒性,并提供可以安全地用于癌症治疗的新型血液处理材料,因为该血液处理材料具有与脂多糖类似的抗肿瘤效果 衍生自革兰氏阴性细菌的细胞壁,但没有致命的影响。